drugset / Trial / NCT00767520
Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine whether exemestane plus dasatinib will be well-tolerated and will increase progression-free survival (PFS) in the treatment of advanced estrogen-receptor positive (ER+) breast cancer after disease progression (PD) on a non-steroidal aromatase inhibitor (NSAI).
Timeline
- Start
- 2009-02
- Primary completion
- 2011-03
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | dasatinib anhydrous | Small molecule | 100 mg | Oral |
| Comparator | Exemestane | Small molecule | 25 mg | Oral |